Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Magenta Therapeutics revenue
Magenta Therapeutics's revenue is $6.2 million.
What is Magenta Therapeutics's revenue?
- Magenta Therapeutics has 125 employees, and the revenue per employee ratio is $49,880.
- Magenta Therapeutics's peak quarterly revenue was $1.9M in 2024(q2).
- Magenta Therapeutics peak revenue was $6.2M in 2024.
- Magenta Therapeutics annual revenue for 2024 was 6.2M, 120.63% growth from 2023.
- Magenta Therapeutics's revenue growth from 2023 to 2024 is 120.63%.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Magenta Therapeutics financing
Magenta Therapeutics received early financing of $48.5M on 2016-11-16.
| Series | Round size | Date |
|---|---|---|
| Series A | $48.5M | 11/2016 |
| Series B | $50M | 05/2017 |
| Series C | $52M | 04/2018 |
| Post Ipo Equity | $69M | 06/2020 |
| Post Ipo Equity | $86.4M | 05/2021 |
Magenta Therapeutics investors
| Investors | Security type |
|---|---|
| Third Rock Ventures | Series A |
| Atlas Venture | Series A |
| Access Industries | Series B |
| Partners Innovation Fund | Series B |
| Be The Match BioTherapies | Series B |
| Third Rock Ventures | Series B |
| GV | Series B |
| Atlas Venture | Series B |
| Casdin Capital | Series B |
| Eventide Asset Management | Series C |
| Access Industries | Series C |
| EcoR1 Capital, LLC | Series C |
| The Watermill Group | Series C |
| Be The Match BioTherapies | Series C |
| Casdin Capital | Series C |
| Great Point Partners | Post Ipo Equity |
| Janus Henderson Investors | Post Ipo Equity |
| OrbiMed Advisors | Post Ipo Equity |
| TCG Crossover | Post Ipo Equity |
| Deep Track Capital LP | Post Ipo Equity |
Magenta Therapeutics competitors
Magenta Therapeutics's top competitor, Biohaven Pharmaceuticals, earned an annual revenue of $462.5M.
Magenta Therapeutics's smallest competitor is Good Start Genetics with revenue of $1.9M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Biohaven Pharmaceuticals | - | $462.5M | 825 | - |
| Good Start Genetics | - | $1.9M | 37 | - |
| Catalyst Biosciences | - | $105.8M | 21 | - |
| Numerate | - | $8.3M | 30 | - |
| Epizyme | - | $37.4M | 124 | - |
| Chrono Therapeutics | - | $5.0M | 30 | - |
| Aptuit | - | $100.0M | 1,733 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Magenta Therapeutics highest paying jobs
Zippia gives an in-depth look into the details of Magenta Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Magenta Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at Magenta Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Magenta Therapeutics. The data presented on this page does not represent the view of Magenta Therapeutics and its employees or that of Zippia.
Magenta Therapeutics may also be known as or be related to MAGENTA THERAPEUTICS, INC., Magenta Therapeutics, Magenta Therapeutics Inc and Magenta Therapeutics, Inc.